Amgen Inc. v. Sandoz Inc., No. 15-1499 (Fed. Cir. July 21, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal presents issues of first impression rela t- ing to the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), Pub. L. No. 111- 148, §§ 7001–7003, 124 Stat. 119, 804– 21 (2010). Amgen Inc. and Amgen Manufacturing Ltd. (collectively, “Amgen”) appeal from the decision of the United States District Court for the Northern District of California (1) dismissing Amgen’s state law claims of unfair competition and conversion with prejudice because Sandoz Inc.